Autosomal dominant hypocalcemia: genes and variants
Autosomal dominant hypocalcemia is linked to 2 analyzed proteins (CASR and GNA11). 75 DNA variants are known to cause it; 1,163 more are uncertain, and 12 of those already look disease-causing on computable evidence.
Last updated 2026-09-30. Research information, not medical advice.
Also known as: autosomal dominant hypocalcemia 1; Autosomal dominant hypocalcemia 2
Genes linked to Autosomal dominant hypocalcemia
CASR: Extracellular calcium-sensing receptor
It senses extracellular calcium in the parathyroid gland and kidney and adjusts parathyroid-hormone secretion and renal calcium handling accordingly. Loss-of-function variants cause familial hypocalciuric hypercalcemia or neonatal severe hyperparathyroidism, whereas activating variants cause autosomal dominant hypocalcemia.
69 disease-causing and 1,152 uncertain variants in CASR are linked to Autosomal dominant hypocalcemia.
GNA11: Guanine nucleotide-binding protein subunit alpha-11
It transmits signals from Gq-coupled receptors to phospholipase C and downstream calcium and protein-kinase-C pathways. Germline activating variants can cause autosomal dominant hypocalcemia, while somatic activating variants drive uveal melanoma and some vascular lesions.
6 disease-causing and 11 uncertain variants in GNA11 are linked to Autosomal dominant hypocalcemia.
Where Autosomal dominant hypocalcemia variants cluster
- CASR Ligand-binding 1 (LB1) (positions 22–188): 17 of 69 disease-causing changes, 1.6× more than its size predicts.
- CASR Cysteine-rich (CR) (positions 542–612): 9 of 69 disease-causing changes, 2.0× more than its size predicts.
- CASR Transmembrane (positions 806–828): 4 of 69 disease-causing changes, 2.7× more than its size predicts.
- CASR Intracellular loop 3 (ICL3) (positions 790–805): 3 of 69 disease-causing changes, 2.9× more than its size predicts.
- CASR Transmembrane (positions 770–789): 3 of 69 disease-causing changes, 2.3× more than its size predicts.
Known disease-causing variants in Autosomal dominant hypocalcemia
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| CASR R220W | 220 | Ligand-binding 2 (LB2) | Disease-causing (★★) |
| CASR P221L | 221 | Ligand-binding 2 (LB2) | Disease-causing (★★) |
| CASR M1T | 1 | Disease-causing (★★) | |
| CASR M1V | 1 | Disease-causing (★★) | |
| CASR R66C | 66 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR R66H | 66 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR R220Q | 220 | Ligand-binding 2 (LB2) | Disease-causing (★★) |
| CASR L125P | 125 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR F128L | 128 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR R172G | 172 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR R185Q | 185 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR C582S | 582 | Cysteine-rich (CR) | Disease-causing (★★) |
| CASR C582Y | 582 | Cysteine-rich (CR) | Disease-causing (★★) |
| CASR R69H | 69 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR E127A | 127 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR G143E | 143 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR D217Y | 217 | Ligand-binding 2 (LB2) | Disease-causing (★★) |
| CASR Y218C | 218 | Ligand-binding 2 (LB2) | Disease-causing (★★) |
| CASR I555T | 555 | Cysteine-rich (CR) | Disease-causing (★★) |
| CASR F788C | 788 | Transmembrane | Disease-causing (★★) |
| GNA11 R60C | 60 | G-alpha | Disease-causing (★★) |
| CASR S53P | 53 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR G143R | 143 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR E604K | 604 | Cysteine-rich (CR) | Disease-causing (★★) |
| CASR P55L | 55 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR T151M | 151 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR D190G | 190 | Ligand-binding 2 (LB2) | Disease-causing (★★) |
| CASR C395R | 395 | Extracellular | Disease-causing (★★) |
| CASR Q459R | 459 | Extracellular | Disease-causing (★★) |
| CASR R465Q | 465 | Extracellular | Disease-causing (★★) |
| CASR G509R | 509 | Extracellular | Disease-causing (★★) |
| CASR G613E | 613 | Transmembrane | Disease-causing (★★) |
| CASR G670R | 670 | Extracellular | Disease-causing (★★) |
| CASR R680C | 680 | Transmembrane | Disease-causing (★★) |
| CASR V728F | 728 | Transmembrane | Disease-causing (★★) |
| CASR E767K | 767 | Extracellular | Disease-causing (★★) |
| CASR R795W | 795 | Intracellular loop 3 (ICL3) | Disease-causing (★★) |
| CASR P798L | 798 | Intracellular loop 3 (ICL3) | Disease-causing (★★) |
| CASR M811V | 811 | Transmembrane | Disease-causing (★★) |
| CASR V817I | 817 | Transmembrane | Disease-causing (★★) |
| CASR F832S | 832 | Extracellular | Disease-causing (★★) |
| CASR R886W | 886 | Interaction with RNF19A | Disease-causing (★★) |
| CASR N178D | 178 | Ligand-binding 1 (LB1) | Disease-causing (★★) |
| CASR R227Q | 227 | Ligand-binding 2 (LB2) | Disease-causing (★★) |
| CASR N802S | 802 | Intracellular loop 3 (ICL3) | Disease-causing (★★) |
| CASR M1R | 1 | Disease-causing (★) | |
| CASR R220P | 220 | Ligand-binding 2 (LB2) | Disease-causing (★) |
| CASR P221S | 221 | Ligand-binding 2 (LB2) | Disease-causing (★) |
| GNA11 T54M | 54 | G-alpha | Disease-causing (★) |
| CASR R551K | 551 | Cysteine-rich (CR) | Disease-causing (★) |
| CASR G557E | 557 | Cysteine-rich (CR) | Disease-causing (★) |
| CASR F788L | 788 | Transmembrane | Disease-causing (★) |
| CASR Y95C | 95 | Ligand-binding 1 (LB1) | Disease-causing (★) |
| CASR E297K | 297 | Ligand-binding 2 (LB2) | Disease-causing (★) |
| CASR G549R | 549 | Cysteine-rich (CR) | Disease-causing (★) |
| GNA11 R149H | 149 | G-alpha | Disease-causing (★) |
| CASR E228Q | 228 | Ligand-binding 2 (LB2) | Disease-causing (★) |
| CASR Q245R | 245 | Ligand-binding 2 (LB2) | Disease-causing (★) |
| CASR C562F | 562 | Cysteine-rich (CR) | Disease-causing (★) |
| CASR I839N | 839 | Transmembrane | Disease-causing (★) |
Showing 60 of 75.
Uncertain variants in Autosomal dominant hypocalcemia that look disease-causing
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| CASR Y218H | 218 | Ligand-binding 2 (LB2) | Conflicting reports (★) | +6: 7 other pathogenic changes within 3 positions; Y218C at the same position is pathogenic; seen in 6.8e-07 of gnomAD DNA copies; AlphaMissense 1.00 |
| CASR C582R | 582 | Cysteine-rich (CR) | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; C582S at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| CASR G549E | 549 | Cysteine-rich (CR) | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; G549R at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| CASR Y218N | 218 | Ligand-binding 2 (LB2) | Uncertain (★) | +6: 7 other pathogenic changes within 3 positions; Y218C at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| CASR R69C | 69 | Ligand-binding 1 (LB1) | Uncertain (★★) | +6: 3 other pathogenic changes within 3 positions; R69H at the same position is pathogenic; seen in 6.8e-07 of gnomAD DNA copies; AlphaMissense 0.92 |
| CASR P55S | 55 | Ligand-binding 1 (LB1) | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; P55L at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.95 |
| CASR D217G | 217 | Ligand-binding 2 (LB2) | Uncertain (★★) | +6: 5 other pathogenic changes within 3 positions; D217Y at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.76 |
| CASR I554F | 554 | Cysteine-rich (CR) | Uncertain (★★) | +6: 4 other pathogenic changes within 3 positions; I554T at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.78 |
| CASR G557R | 557 | Cysteine-rich (CR) | Uncertain (★) | +6: 3 other pathogenic changes within 3 positions; G557E at the same position is pathogenic; seen in 6.8e-07 of gnomAD DNA copies; AlphaMissense 0.79 |
| CASR G557W | 557 | Cysteine-rich (CR) | Uncertain (★) | +6: 3 other pathogenic changes within 3 positions; G557E at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.79 |
| CASR F128I | 128 | Ligand-binding 1 (LB1) | Uncertain (★) | +6: 3 other pathogenic changes within 3 positions; F128L at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.74 |
| CASR P221Q | 221 | Ligand-binding 2 (LB2) | Uncertain (★) | +6: 6 other pathogenic changes within 3 positions; P221L at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.82 |
Which prediction tools work for Autosomal dominant hypocalcemia
How often each tool ranks a disease-causing variant above a harmless one (AUROC × 100).
- CADD: 98 out of 100
- PolyPhen-2: 96 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CATVariant: 94 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- phyloP: 92 out of 100
- SIFT: 85 out of 100
Same protein, different disease
- Familial hypocalciuric hypercalcemia is also caused by CASR variants; they fall partly in the same places as the Autosomal dominant hypocalcemia variants (81 disease-causing).
- Nephrolithiasis/nephrocalcinosis is also caused by CASR variants; they fall in the same places as the Autosomal dominant hypocalcemia variants (14 disease-causing).
- Neonatal severe primary hyperparathyroidism is also caused by CASR variants; they fall in the same places as the Autosomal dominant hypocalcemia variants (11 disease-causing).
- Familial hyperparathyroidism or Hypocalciuric hypercalcaemia is also caused by CASR variants; they fall partly in the same places as the Autosomal dominant hypocalcemia variants (5 disease-causing).
Diseases related to Autosomal dominant hypocalcemia
- Familial hypocalciuric hypercalcemia, also linked to CASR and GNA11
- Familial hypoparathyroidism, also linked to CASR and GNA11
- Hypertrophic cardiomyopathy, also linked to CASR
- Epilepsy, idiopathic generalized, susceptibility to, 13, also linked to CASR
- Idiopathic generalized epilepsy, also linked to CASR
- Nephrolithiasis/nephrocalcinosis, also linked to CASR
- Vascular malformation, also linked to GNA11
- Neonatal severe primary hyperparathyroidism, also linked to CASR
- Familial hyperparathyroidism or Hypocalciuric hypercalcaemia, also linked to CASR
- Familial multiple nevi flammei, also linked to GNA11
- Chronic kidney disease, also linked to CASR
Frequently asked questions
Which genes are linked to Autosomal dominant hypocalcemia?
In CATVariant, Autosomal dominant hypocalcemia is linked to 2 analyzed proteins: CASR (Extracellular calcium-sensing receptor) and GNA11 (Guanine nucleotide-binding protein subunit alpha-11).
How many genetic variants are linked to Autosomal dominant hypocalcemia?
1,260 variants: 75 are classified as disease-causing (pathogenic or likely pathogenic) in ClinVar and 1,163 are of uncertain significance or have conflicting reports.
Which uncertain variants in Autosomal dominant hypocalcemia look disease-causing?
12 uncertain variants reach the likely-pathogenic range of the ACMG/AMP points scale on computable evidence, for example CASR Y218H, CASR C582R, CASR G549E, CASR Y218N and CASR R69C. These are leads for expert review, not diagnoses.
Which variant effect predictor works best for Autosomal dominant hypocalcemia?
Among tools not trained on clinical labels, CADD separates this disease's known disease-causing variants from harmless ones best (AUROC 0.98, based on 31 disease-causing and 11 harmless variants).
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from the latest public CATVariant analysis of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center